Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer

被引：0
|
作者：
Van Raemdonck, E.
Berteloot, P.
Laenen, A.
Han, S.
Van Nieuwenhuysen, E.
Salihi, R.
Concin, N.
Vergote, I.
Floris, G.
Wildiers, H.
Punie, K.
Neven, P.
机构：
[1] KU Leuven Univ Leuven, Leuven, Belgium
[2] KU Leuven Univ Leuven, Lab Translat Cell & Tissue Res, Leuven, Belgium
[3] Univ Leuven, Dept Pathol, Leuven, Belgium
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-PD3-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD3-09
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
    Palm, Christiane
    Connolly, Catherine E. E.
    Masser, Regina
    Sgier, Barbara Padberg
    Karamitopoulou, Eva
    Simon, Quentin
    Bode, Beata
    Tinguely, Marianne
    DIAGNOSTICS, 2023, 13 (01)
  • [32] Methodology matters - prognostic significance of HER2 protein expression versus HER2 gene amplification in metastatic breast cancer
    Todorovic-Rakovic, N.
    Jovanovic, D.
    Neskovic-Konstantinovic, Z.
    Nikolic-Vukosavljevic, D.
    EJC SUPPLEMENTS, 2008, 6 (09): : 160 - 160
  • [33] HER2/neu status in primary breast cancer and in metastatic site as detected using FNA
    Giotta, Francesco
    Asselti, Maria Consilia
    Petroni, Stella
    Popescu, Onsina
    Rubini, Vincenza
    Latorre, Agnese
    Lorusso, Vito
    Gadaleta, Cosimo
    Simone, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Meta Analysis of Discordant HER2 Status in Matched Primary and Metastatic Breast Cancer.
    Richter, S.
    Zandvakili, A.
    CANCER RESEARCH, 2011, 71
  • [35] Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer
    Janni, W.
    Schramm, A.
    Friedl, T. W. P.
    Schochter, F.
    Huober, J.
    Rack, B.
    Alunni-Fabbroni, M.
    Fasching, P. A.
    Taran, F-A
    Hartkopf, A.
    Schneeweiss, A.
    Mueller, V.
    Aktas, B.
    Krawczyk, N.
    Pantel, K.
    Fehm, T.
    CANCER RESEARCH, 2016, 76
  • [36] The Effect of HER2 Amplification in HER2+Breast Cancer
    Lee, M. K.
    Hurvitz, S. A.
    Tran, B. N.
    Fu, Y.
    Chung, D. U.
    Gornbein, J.
    Apple, S. K.
    Chang, H. R.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S45 - S45
  • [37] Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer
    Aurilio, Gaetano
    Sandri, Maria Teresa
    Pruneri, Giancarlo
    Zorzino, Laura
    Botteri, Edoardo
    Munzone, Elisabetta
    Adamoli, Laura
    Facchi, Giuseppina
    Cullura, Daniela
    Verri, Elena
    Rocca, Maria Cossu
    Zurrida, Stefano
    Iacovelli, Roberto
    Nole, Franco
    FUTURE ONCOLOGY, 2016, 12 (17) : 2001 - 2008
  • [38] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose, Ron
    Kavuri, Shyam M.
    Searleman, Adam C.
    Shen, Wei
    Shen, Dong
    Koboldt, Daniel C.
    Monsey, John
    Goel, Nicholas
    Aronson, Adam B.
    Li, Shunqiang
    Ma, Cynthia X.
    Ding, Li
    Mardis, Elaine R.
    Ellis, Matthew J.
    CANCER DISCOVERY, 2013, 3 (02) : 224 - 237
  • [39] Clinical significance of metastatic-tumor HER2 status in patients with HER2-positive primary breast cancer
    Niikura, N.
    Liu, J.
    Hayashi, N.
    Mittendorf, E. A.
    Gong, Y.
    Palla, S. L.
    Tokuda, Y.
    Gonzalez-Angulo, A. M.
    Hortobagyi, G. N.
    Ueno, N. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] DISCORDANCE BETWEEN HORMONE RECEPTORS AND HER2 STATUS IN BREAST CANCER PATIENTS RELAPSE
    Roque, Katia
    Otoya, Iris
    Valdivieso, Natalia
    Morante, Zaida
    Fuentes, Hugo
    Neciosup, Silvia
    Gomez, Henry
    Cotito, Jorge
    Ziegler, Gonzalo
    Pena, Estefania
    Vidaurre, Tatiana
    de Mello, Ramon Andrade
    Castaneda, Carlos
    CANCER RESEARCH, 2024, 84 (09)
12345